27 related articles for article (PubMed ID: 7517443)
1. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.
Lin GW; Yao XD; Zhang SL; Dai B; Ma CG; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Qin XJ; Ye DW
Asian J Androl; 2009 Jul; 11(4):443-50. PubMed ID: 19182820
[TBL] [Abstract][Full Text] [Related]
2. Radiation dose-response (a Bayesian model) in the radiotherapy of the localized prostatic adenocarcinoma: the reliability of PSA slope changes as a response surrogate endpoint.
Mohammadpour RA; Yazdani-Charati J; Faghani S; Alizadeh A; Barzegartahamtan M
PeerJ; 2019; 7():e7172. PubMed ID: 31304057
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.
Phak JH; Kim HJ; Kim WC
Prostate Int; 2016 Mar; 4(1):25-9. PubMed ID: 27014661
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
[TBL] [Abstract][Full Text] [Related]
6. Clinical trials in relapsed prostate cancer: defining the target.
Scher HI; Mazumdar M; Kelly WK
J Natl Cancer Inst; 1996 Nov; 88(22):1623-34. PubMed ID: 8931606
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
Zagars GK; Pollack A; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
[TBL] [Abstract][Full Text] [Related]
8. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.
Zagars GK
J Urol; 1994 Nov; 152(5 Pt 2):1786-91. PubMed ID: 7523725
[TBL] [Abstract][Full Text] [Related]
10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
11. Serum prostate-specific antigen in monitoring the response of carcinoma of the prostate to radiation therapy.
Fijuth J; Chauvet B; Vincent P; Félix-Faure C; Reboul F
Radiother Oncol; 1992 Apr; 23(4):236-40. PubMed ID: 1376935
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
Chauvet B; Félix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
[TBL] [Abstract][Full Text] [Related]
13. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it?
Kuban DA; El-Mahdi AM; Schellhammer PF
Semin Radiat Oncol; 1998 Apr; 8(2):72-80. PubMed ID: 9516587
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]